Ivanna Boichuk

Brno, JM, Czech Republic

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 33 publications

Treatment of Erdheim-Chester disease from the perspective in 2026.

Treatment of Erdheim-Chester disease from the perspective in 2026.

Journal: Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti

Published: August 28, 2026

IgG4-related disease - treatment with anti-CD20, anti-CD19 antibodies, and other new drugs.

IgG4-related disease - treatment with anti-CD20, anti-CD19 antibodies, and other new drugs.

Journal: Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti

Published: August 28, 2026

Contribution of bone scintigraphy and PET/CT in the differential diagnosis of bone involvement in a patient with fibrous dysplasia and monoclonal gammopathy of undetermined significance and fibrous dysplasia treatment with denosumab.

Contribution of bone scintigraphy and PET/CT in the differential diagnosis of bone involvement in a patient with fibrous dysplasia and monoclonal gammopathy of undetermined significance and fibrous dysplasia treatment with denosumab.

Journal: Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti

Published: August 28, 2026

Changes in hemostasis and other disorders caused by monoclonal immunoglobulin and/or free light chains.

Changes in hemostasis and other disorders caused by monoclonal immunoglobulin and/or free light chains.

Journal: Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti

Published: May 22, 2026

Cutaneous diseases caused by monoclonal immunoglobulin and/or free light chains (monoclonal gammopathy of cutaneous significance).

Cutaneous diseases caused by monoclonal immunoglobulin and/or free light chains (monoclonal gammopathy of cutaneous significance).

Journal: Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti

Published: May 22, 2026

Treatment of Castleman disease from the perspective of the year 2026.

Treatment of Castleman disease from the perspective of the year 2026.

Journal: Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti

Published: May 04, 2026

EBV-associated plasmacytic variant of Castleman disease: more than a decade-long diagnostic odyssey - a case report.

EBV-associated plasmacytic variant of Castleman disease: more than a decade-long diagnostic odyssey - a case report.

Journal: Ceskoslovenska patologie

Published: April 17, 2026

High-risk genomic features predict extramedullary progression in multiple myeloma with paraskeletal plasmacytomas.

High-risk genomic features predict extramedullary progression in multiple myeloma with paraskeletal plasmacytomas.

Journal: HemaSphere

Published: March 26, 2026

Polyclonal hypergammaglobulinemia, infiltration of the salivary glands, lymphadenopathy, and kidney damage - Mikulicz's disease, Sjögren's syndrome, or Castleman's disease? Case report and overview of differential diagnosis and treatment.

Polyclonal hypergammaglobulinemia, infiltration of the salivary glands, lymphadenopathy, and kidney damage - Mikulicz's disease, Sjögren's syndrome, or Castleman's disease? Case report and overview of differential diagnosis and treatment.

Journal: Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti

Published: January 19, 2026

Monoclonal gammopathy of clinical significance - a group name for diseases caused by monoclonal immunoglobulin and/ or free light chains. A change in the approach to non-malignant gammopathies.

Monoclonal gammopathy of clinical significance - a group name for diseases caused by monoclonal immunoglobulin and/ or free light chains. A change in the approach to non-malignant gammopathies.

Journal: Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti

Published: October 30, 2025

Precision medicine in hemato-oncology - treatment of refractory multiple myeloma with massive extramedullary involvement using BRAF/ MEK inhibitors.

Precision medicine in hemato-oncology - treatment of refractory multiple myeloma with massive extramedullary involvement using BRAF/ MEK inhibitors.

Journal: Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti

Published: October 30, 2025

Description of TEMPI syndrome in Waldenström's macroglobulinemia.

Description of TEMPI syndrome in Waldenström's macroglobulinemia.

Journal: Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti

Published: September 17, 2025

Showing 1-12 of 33

Last Updated: 09/26/2026